Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9017-9025

  Pejovic, Tanja ^a,b   Yates, Jane E ^b   Liu, Hong Y ^a   Hays, Laura E ^b   Akkari, Yassmine ^b   Torimaru, Yumi ^b   Keeble, Winifred ^b   Rathbun, R Keaney ^b   Rodgers, William H ^d   Bale, Allen E ^e   Ameziane, Najim ^f   Zwaan, C Michael ^h   Errami, Abdellatif ^g   Thuillier, Philippe ^b   Cappuccini, Fabio ^a,b   Olson, Susan B ^b   Cain, Joanna M ^a,b   Bagby Jr , Grover C ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MRC HOLLAND   (Netherlands)

^h SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; MITOMYCIN; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHROMOSOMAL INSTABILITY; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CONTROLLED STUDY; CROSS LINKING; FANCONI ANEMIA; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; IMMUNOBLOTTING; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT;

ADULT; AGED; CHROMOSOME BREAKAGE; DNA METHYLATION; DNA, COMPLEMENTARY; EPITHELIAL CELLS; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENE SILENCING; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; MITOMYCIN; OVARIAN NEOPLASMS; OVARY; PROMOTER REGIONS (GENETICS); PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33749465890     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0222     Document Type: Article

References (40)

1. Okamura H, Katabuchi H. Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis. Int Rev Cytol 2005;242:1-54.
2. Mitelman F, Mertens F, Johansson B. Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Genes Chromosomes Cancer 2005;43:350-66.
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
4. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991;139:777-85.
5. Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukumoto M. c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression. Int J Cancer 1992;50:828-33.
6. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
7. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
8. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7.
9. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-7.
10. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 1999;96:214-9.
11. Schorge JO, Miller YB, Qi LJ, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000;76:369-72.
12. McCoy ML, Mueller CR, Roskelley CD. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:72.
13. Meetei AR, Levitus M, Xue Y, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004;36:1219-24.
14. Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005;37:934-5.
15. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 2005;37:931-3.
16. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001;7:249-62.
17. Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002;100:2414-20.
18. Hussain S, Wilson JB, Medhurst AL, et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet 2004;13:1241-8.
19. Shimamura A, de Oca RM, Svenson JL, et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 2002;100:4649-54.
20. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
21. Houghtaling S, Timmers C, Noll M, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003;17:2021-35.
22. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med 2003;9:568-74.
23. U.S. Preventive Services Task Force recommendations. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 2005;143:147.
24. Saito H, Hammond AT, Moses RE. Hypersensitivity to oxygen is a uniform and secondary defect in Fanconi anemia cells. Mutat Res 1993;294:255-62.
25. Williams DA, Rosenblatt MF, Beier DR, Cone RD. Generation of murine stromal cell lines supporting hematopoietic stem cell proliferation by use of recombinant retrovirus vectors encoding simian virus 40 large T antigen. Mol Cell Biol 1988;8:3864-71.
26. Naf D, Kupfer GM, Suliman A, Lambert K, D'Andrea AD. Functional activity of the Fanconi anemia protein FAA requires FAC binding and nuclear localization. Mol Cell Biol 1998;18:5952-60.
27. Kuang Y, Garcia-Higuera I, Moran A, Mondoux M, Digweed M, D'Andrea AD. Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. Blood 2000;96:1625-32.
28. Pang Q, Keeble W, Christianson TA, Faulkner GR, Bagby GC. FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-γ/TNF-α-mediated cytotoxicity. EMBO 2001;20:4478-89.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods 2001;25:402-8.
30. Selzer RR, Richmond TA, Pofahl NJ, et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 2005;44:305-19.
31. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72.
32. Nygren AO, Ameziane N, Duarte HM, et al. Methylation-speciflc MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005;33:e128.
33. Scheuten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
34. Pestell K, Medlow C, Titley J, Kelland L, Walton M. Characterisation of the P53 status, Bcl-2 expression, and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 1998;77:913-8.
35. van Beusechem V, van den Doel P, Grill J, Pinedo H, Gerritsen W. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62:6165-71.
36. Offit K. Clinical cancer genetics: risk counseling and management New York: Wiley-Liss, Inc.; 1998. p. 115-24.
37. Zhang GL, Xu KL. Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China. Int J Gynecol Cancer 2002;12:198-201.
38. Bagby GC, Jr. Genetic basis of Fanconi anemia. Curr Opin Hematol 2003;10:68-76.
39. Lensch MW, Rathbun RK, Olson SB, Jones GR, Bagby GC, Jr. Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemia. Leukemia 1999;13:1784-9.
40. Bagby GC, Olson SB. Cisplatin and the sensitive cell. Nat Med 2003;9:513-4.